Mechanistic study of the Tβ4/SLC7A11 signaling pathway regulating breast cancer evolution.

This study investigated the role of Thymosin β4 (Tβ4) in breast cancer progression and its molecular mechanism. The researchers found that Tβ4 is significantly overexpressed in breast cancer tissues and cell lines, with high expression correlating with poorer clinical outcomes. Using functional experiments, the study showed that elevated Tβ4 promotes cancer cell proliferation, migration, epithelial-mesenchymal transition (EMT), and angiogenesis, while inhibiting apoptosis. Mechanistically, the study identified that Tβ4 directly regulates SLC7A11, a cystine/glutamate antiporter, which in turn enhances glutathione biosynthesis and suppresses lipid peroxidation — effectively inhibiting ferroptosis (an iron-dependent form of programmed cell death). Rescue experiments, conducted both in cell cultures (in vitro) and animal models (in vivo), demonstrated that silencing SLC7A11 reversed the cancer-promoting effects of Tβ4. The study concludes that a novel Tβ4/SLC7A11 signaling axis modulates ferroptosis resistance and contributes to breast cancer malignancy. Limitations include reliance on preclinical models, and no human clinical trials were conducted, leaving the translational relevance to patients yet to be established.

Why this grade: The study combines in vitro cell-line experiments and in vivo animal models but includes no human clinical trial data, placing it in the preclinical mixed evidence category.